Teva Chief Looks Beyond $40.5 Billion Allergan Deal for Growth - (Bloomberg via NewsPoints Desk)

  • Teva pledged to continue developing innovative medicines following its acquisition of Allergan's generics business, Bloomberg reported Wednesday.

  • Teva CEO Erez Vigodman said the transaction "doesn't mean we confine our business to just generics," adding "the strategy and vision are much broader."

  • Vigodman stated that the company will target "attractive specialty assets, or branded drug assets or pipeline assets."

  • The Copaxone manufacturer has also agreed to acquire Allergan's generics distribution unit for $500 million.

  • Meanwhile, Vigodman indicated that patients are more informed today and seek more from companies than just drugs.

  • "The surest sign an industry is on the verge of disruption is the proliferation of tech entrepreneurs backed by venture capital and driven by consumer demand," Vigodman remarked, continuing "that’s exactly what we're seeing in our industry."

To read more NewsPoints articles, click here.